Bridgebio Pharma Inc
Închisă
SectorSănătate
72.09 -0.47
Rezumat
Modificarea prețului
24h
Minim
71.83
Maxim
72.67
Venit | 11M -156M |
|---|---|
Vânzări | 28M 222M |
EPS | -0.78 |
Marjă de profit | -70.082 |
Angajați | 999 |
EBITDA | -24M -137M |
Următoarele câștiguri | 28 oct. 2026 |
|---|
Capitalizare de piață | -2B 15B |
|---|---|
Deschiderea anterioară | 72.56 |
Închiderea anterioară | 72.09 |
Sentimentul știrilor
By Acuity
72%
28%
301 / 339 Clasament în Healthcare
Bridgebio Pharma Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Bridgebio Pharma Inc Așteptări
Sentiment
By Acuity
301 / 339 Clasament în Sănătate
Sentimentul știrilor
Evidențe de scădere
Volatilitate
Sub medie
Volumul știrilor (RCV)
Sub medie
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre Bridgebio Pharma Inc
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
